Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

A-TANGO

Financiado

Cerrado

NOVEL TREATMENT OF ACUTE ON CHRONIC LIVER FAILURE USING SYNERGISTIC ACTION OF G...

NOVEL TREATMENT OF ACUTE ON CHRONIC LIVER FAILURE USING SYNERGISTIC ACTION OF G CSF AND TAK 242 In Europe, about 30,000 people die every year from alcohol related cirrhosis, a form of chronic, non- communicable disease. The patients that are at highest risk of death are those with superimposed alcoholic hepatitis (AH) who do... ver más

28/02/2026

EF CLIF

6M€

Presupuesto del proyecto: 6M€

Líder del proyecto

EUROPEAN FOUNDATION FOR THE STUDY OF CHRONIC... No se ha especificado una descripción o un objeto social para esta compañía.

Fecha límite participación Sin fecha límite de participación.

Ver 13 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2021-01-18

SC1-BHC-08-2020: New interventions for Non-Communica...

I+D

Cerrada hace 5 años

0% 94% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

13 Participantes

EF CLIF

424.13K€ | Lider

ELPA

44.30K€ | Participante

UNIVERSITY COLLEGE LONDON

582.85K€ | Participante

CONCENTRIS RESEARCH MANAGEME...

428.83K€ | Participante

Proyectos interesantes

RTI2018-096748-B-I00

Medical Technol...

Data Science

109K€ Cerrado

SAF2017-85877-R

Medical Technol...

Data Science

182K€ Cerrado

SAF2014-54191-R

Medical Technol...

Data Science

157K€ Cerrado

DECISION

Medical Technol...

Data Science

6M€ Cerrado

HEPCIR

Medical Technol...

Data Science

2M€ Cerrado

FIBCAN

Medical Technol...

Cancer Research

2M€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 61 meses Fecha Inicio: 2021-01-18
Fecha Fin: 2026-02-28

Líder del proyecto

EUROPEAN FOUNDATION FOR THE STUDY OF CHRONIC... No se ha especificado una descripción o un objeto social para esta compañía.

Presupuesto del proyecto 6M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto In Europe, about 30,000 people die every year from alcohol related cirrhosis, a form of chronic, non- communicable disease. The patients that are at highest risk of death are those with superimposed alcoholic hepatitis (AH) who do not respond to therapy and develop acute on chronic liver failure (ACLF), a newly described syndrome characterised by multiorgan failure. Treatment of ACLF is an unmet need. Based upon their clinical and pre-clinical studies, the A-TANGO consortium aims to perform Phase 2 clinical trials of a novel, patented and innovative therapeutic strategy by repurposing a toll-like 4 receptor antagonist (TAK242, Technology Readiness Level (TRL) 8), which targets inflammation, and combining it with granulocyte colony-stimulating factor (G-CSF, TRL9) that improves hepatocyte proliferation (G-TAK, TRL4). A successful trial will advance G-TAK to TRL8. Additionally, A-TANGO aims to discover novel biomarkers for patient selection and defining prognosis, building health economics models and reimbursement strategies to allow maximal dissemination and exploitation. The A-TANGO Consortium includes the inventors of G-TAK (UCL, Charité, ULEI and LUMC) and will deliver the project aims through EFCLIF, which has a network of 110 European hospitals. YAQ and HPX are SME’s that own the background IP and will ensure regulatory approval, study Sponsorship and drug supply. APHP and IMAC will deliver the economic models. Concentris will manage the project and together with EASL, CHX and ELPA will engage with patients, initiate widespread dissemination activities and allow exploitation of the results. Gender balance will be maintained throughout the project duration. A-TANGO will achieve the expected impacts of producing meaningful advances in clinical practice by reducing the mortality and improving the quality of life of patients with ACLF whilst reducing disease burden of individual patients and health care systems following validation in late stage clinical trials.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores